SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-166859
Filing Date
2023-06-14
Accepted
2023-06-14 16:09:02
Documents
12
Period of Report
2023-06-13
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K d518831d8k.htm   iXBRL 8-K 32888
  Complete submission text file 0001193125-23-166859.txt   154911

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA tals-20230613.xsd EX-101.SCH 2845
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE tals-20230613_lab.xml EX-101.LAB 17979
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tals-20230613_pre.xml EX-101.PRE 11255
6 EXTRACTED XBRL INSTANCE DOCUMENT d518831d8k_htm.xml XML 3345
Mailing Address 93 WORCESTER STREET WELLESLEY MA 02481
Business Address 570 PRESTON ST. SUITE 400 LOUISVILLE KY 40202 502-398-9250
Talaris Therapeutics, Inc. (Filer) CIK: 0001827506 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40384 | Film No.: 231014182
SIC: 2836 Biological Products, (No Diagnostic Substances)